Refractory Plasmablastic Lymphoma
2 clinical trials · Condition
◉ Watch Refractory Plasmablastic Lymphoma
| Record | Firm | Date |
|---|---|---|
| Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma (NCT04676360) | Jacob Soumerai, MD | 2021-07-01 |
Track Refractory Plasmablastic Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.